Pharmaceutical

Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval

Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.

May 19, 2024 - 04:00
Moxifloxacin by Laboratorios Sophia for Bacterial Conjunctivitis: Likelihood of Approval
Moxifloxacin is under clinical development by Laboratorios Sophia and currently in Phase I for Bacterial Conjunctivitis.
Read the original article

Tags:

Previous Article

CinDome Pharma secures $40m to advance gastroparesis treatment

Next Article

TNT-119 by Eliem Therapeutics for Membranous Glomerulonephritis: Likelihood of A...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer

STAT+: Allogene to pursue new strategy for development ...

Jan 4, 2024

ILution travoprost by Glaukos for Open-Angle Glaucoma: Likelihood of Approval

ILution travoprost by Glaukos for Open-Angle Glaucoma: ...

Jun 20, 2024

Alvotech and Bioventure gain approval for Humira biosimilar in Egypt

Alvotech and Bioventure gain approval for Humira biosim...

Aug 30, 2023